A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

NCT02072213 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GL2702 GLARS-NF1
DRUG: Omix Ocas

Sponsor

GL Pharm Tech Corporation